News

Two cases of progressive familial intrahepatic cholestasis type 3 (PFIC3) with markedly different ages of disease onset due to new mutations in the ABCB4…

Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous names — NAFL, NASH, or…

Kidney and blood vessel problems are common in people with Alagille syndrome, and while these often cause few to no symptoms, they can be…

Treatment with linerixibat, an oral medication in development by GlaxoSmithKline (GSK), led to significant reductions in pruritus, or itching, among adults with primary…

Women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver complication, have significantly higher scores of two whole-body inflammation biomarkers than women…

Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…

Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children with biliary atresia, including…

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed…

After 2.5 years of Livdelzi (seladelpar) treatment, more than 4 in 5 adults with primary biliary cholangitis (PBC) saw meaningful reductions in liver…

Nearly 1.5 years of treatment with Bylvay (odevixibat) effectively reduces itching and liver damage markers, and improves growth and sleep in people with…